Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Themes Biotech

Revolutionary Al Model Foresees Dementia Years Ahead

by Team Lumida
June 11, 2024
in Biotech, Health and Longevity
Reading Time: 3 mins read
A A
0
an abstract image of a sphere with dots and lines

Photo by Growtika on Unsplash

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

  1. New AI model predicts dementia up to 9 years early with 82% accuracy.
  2. Early detection could allow for timely interventions, potentially preventing dementia progression.
  3. Researchers emphasize the need for further validation across diverse populations.

What Happened?

Researchers at Queen Mary University of London developed a new machine learning model that predicts dementia with over 80% accuracy up to nine years before diagnosis. Analyzing 1,111 fMRI scans, the model identifies changes in the brain’s default mode network (DMN), particularly when a person is at rest.

The study, published in Nature Mental Health, included 81 individuals who later developed dementia and 1,030 matched controls. The model accurately predicted dementia within a two-year window before diagnosis.

Why It Matters?

This breakthrough offers a significant advancement in early dementia detection. Early diagnosis could lead to timely interventions, potentially delaying or preventing the onset of dementia.

Dr. Claire Sexton of the Alzheimer’s Association emphasized that Alzheimer’s is linked to decreased functional connectivity within the DMN, aligning with these findings. Early detection is crucial as it provides a chance for interventions before significant cognitive decline occurs.

What’s Next?

Researchers aim to validate the model across more diverse populations and different types of dementia, including frontotemporal and Lewy body dementias. Current limitations include the study’s predominantly white, healthier-than-average cohort.

Neurologists like Clifford Segil stress the need for consistent reproducibility of fMRI results. While no neuroprotective medications are available yet, early detection models like this one could guide future clinical trials, ensuring the right candidates receive new treatments as they emerge.

Source: Medical News Today
Tags: Alzheimer'sDementiafMRIMedical AI
Previous Post

Now Economists Predict Just One Rate Cut This Year

Next Post

Commercial Real Estate: Are Office Spaces the Next Big Financial Risk?

Recommended For You

America’s Protein Obsession Fuels a Booming Market, But Experts Are Concerned

by Team Lumida
4 weeks ago
black magnifying glass on white and brown marble table

Key Takeaways: Powered by lumidawealth.com Americans are consuming protein in unprecedented ways, with food companies introducing protein-infused products like chips, candy, coffee, and even water. The trend is driven...

Read more

Is Covid Accelerating Cognitive Decline? Long-Covid Patients Face Alarming Risks

by Team Lumida
1 month ago
Pandemic Aftershocks: Why Illnesses Are Surging Worldwide

Key Takeaways: Powered by lumidawealth.com Millions of long-Covid patients continue to experience cognitive difficulties, with some being diagnosed with mild cognitive impairment (MCI), a condition that can precede dementia...

Read more

U.S. Risks Losing Biotech Leadership to China, Congressional Report Warns

by Team Lumida
1 month ago
woman holding test tubes

Key Takeaways: Powered by lumidawealth.com A congressional commission has urged the U.S. to invest at least $15 billion in biotechnology research and manufacturing over the next five years to...

Read more

Emerging Drugs from Lilly, Amgen, and Novartis Target Untreatable Cholesterol Linked to Heart Disease

by Team Lumida
1 month ago
white and blue medication pill blister pack

Key Takeaways: Powered by lumidawealth.com Lipoprotein(a), a genetic cholesterol variant untreatable by statins, increases the risk of heart attacks and strokes by 2-3 times for 1-2 billion people worldwide....

Read more

Doctors and Patients Struggle With Trust Amid a Broken Healthcare System

by Team Lumida
2 months ago
person sitting while using laptop computer and green stethoscope near

Key Takeaways: Powered by lumidawealth.com Trust between doctors and patients is eroding, with both sides frustrated by systemic issues like rushed appointments, corporate quotas, and communication breakdowns. Doctors cite...

Read more

U.S. Drug Overdose Deaths Decline by 25%, Marking Progress in the Fentanyl Crisis

by Team Lumida
2 months ago
round white pills

Key Takeaways: Powered by lumidawealth.com Overdose deaths in the U.S. dropped by 25% in the 12 months ending October 2024, with 82,000 fatalities reported. The decline is largely driven...

Read more

AstraZeneca Acquires EsoBiotec for $1 Billion to Strengthen Cell-Therapy Portfolio

by Team Lumida
2 months ago
vitamin b 12 100 mg

Key Takeaways: Powered by lumidawealth.com AstraZeneca will pay $425 million upfront, with an additional $575 million tied to milestones. The acquisition includes EsoBiotec’s innovative in vivo cell therapy platform....

Read more

Retirement Health Worries: Navigating Dementia and Heart Risks in the Golden Years

by Team Lumida
2 months ago
woman in purple polo shirt wearing eyeglasses

Key Takeaways: Powered by lumidawealth.com Retirement often brings increased focus on health concerns, including cognitive decline and heart disease. Family history plays a significant role in health risks, prompting...

Read more

CVS Bets on Pharmacy-First Strategy with Smaller, Streamlined Stores

by Team Lumida
2 months ago
CVS Bets on Pharmacy-First Strategy with Smaller, Streamlined Stores

Key Takeaways: Powered by lumidawealth.com CVS is launching 12 smaller stores focused on pharmacy services, cutting back on traditional retail offerings. The move reflects a response to declining retail...

Read more

TreeHouse Foods Faces Slowdown as Shoppers Cut Back on Even Cheaper Groceries

by Team Lumida
3 months ago
high-angle photography of grocery display gondola

Key Takeaways Powered by lumidawealth.com TreeHouse Foods, a major supplier of private-label goods for retailers like Walmart and Target, is experiencing slower sales growth as inflation-weary consumers reduce spending...

Read more
Next Post
tall trees in front of high-rise buildings

Commercial Real Estate: Are Office Spaces the Next Big Financial Risk?

a close up of the front grill of a car

General Motors Cuts EV Output, Focuses on Shareholders with Massive Buyback

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

woman in purple polo shirt wearing eyeglasses

Retirement Health Worries: Navigating Dementia and Heart Risks in the Golden Years

March 10, 2025
white metal shelf with food packs

Retail Giants Tighten Grip: Walmart, Amazon, and Costco Reshape American Retail Landscape

January 2, 2025
Reckitt Benckiser Beats Profit Expectations Despite Sales Decline, Eyes Modest Growth in 2025

Reckitt Benckiser Beats Profit Expectations Despite Sales Decline, Eyes Modest Growth in 2025

March 6, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018